Loading AI tools
Chemical compound From Wikipedia, the free encyclopedia
Solabegron (code name GW-427,353) is a drug which acts as a selective agonist for the β3 adrenergic receptor. It is being developed for the treatment of overactive bladder and irritable bowel syndrome.[1][2][3] It has been shown to produce visceral analgesia by releasing somatostatin from adipocytes.[4][5]
Clinical data | |
---|---|
Other names | 3-[3-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethylamino]phenyl]benzoic acid |
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII |
|
KEGG | |
ChEBI | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C23H23ClN2O3 |
Molar mass | 410.90 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Solabegron was discovered by GlaxoSmithKline and acquired by AltheRx in March 2011. Solabegron relaxes the bladder smooth muscle by stimulating β3 adrenoceptors, a novel mechanism compared with older established drug treatments for overactive bladder syndrome such as the anticholinergic agents. Astellas Pharma has developed the first commercially available β3 adrenergic receptor, mirabegron, which is now licensed in Japan[6] and the U.S.[7] exclusively for treatment of overactive bladder syndrome.
A Phase II study of solabegron for overactive bladder (OAB) looked at 258 patients with moderate-to-severe incontinence experiencing an average of 4.5 wet episodes per day. Results demonstrated a statistically significant improvement with solabegron as compared with placebo, as measured by the percentage reduction of the number of wet episodes and the absolute number of daily voids.
A Phase II study for irritable bowel syndrome (IBS) evaluated 102 patients with IBS. Solabegron demonstrated significant reduction in pain associated with the disorder and a trend for greater improvement in the quality of life, when compared with a placebo.
Both Phase II studies indicated a tolerability profile for solabegron that was similar to placebo. This drug does not bind to acetylcholine receptors so side effects are expected to be minor.
AltheRx is currently preparing to advance solabegron into a large clinical study in OAB.
Seamless Wikipedia browsing. On steroids.
Every time you click a link to Wikipedia, Wiktionary or Wikiquote in your browser's search results, it will show the modern Wikiwand interface.
Wikiwand extension is a five stars, simple, with minimum permission required to keep your browsing private, safe and transparent.